Publications by authors named "John D Imig"

Claim this Profile
N
NF Erythroid 2-Related Factor 2 Peroxisome Proliferator-Activated Receptor-γ Crosstalk: Reprogramming Monocytic Myeloid-Derived Suppressor Cells in Kidney Disease.
John D Imig

Kidney360· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual acting inhibitor of soluble epoxide hydrolase and Cyclooxygenase-2, attenuates glomerular injury in renal hypoplasia mice.
Md Abdul Hye Khan, Samaneh Goorani, Anna Atamanchuk, Wojceich Jankiewicz, Michael M Yeboah, John D Imig

Eur J Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage.
Abhishek Mishra, Marcus de Bourg, Rawand S Mohamed, Md Abdul Hye Khan, Tsigereda Weldemichael, John D Imig

Biomolecules· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral-obstructed mice.
Henry A Palfrey, Samaneh Goorani, Abhishek Mishra, Md Abdul Hye Khan, Baku Acharya, John D Imig

J Pharmacol Exp Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of hypertension-induced renal vascular dysfunction through a p66Shc-targeted mechanism.
Bradley Miller, John D Imig, Mengjie Li, Perrin Schupbach, Sukyung Woo

Am J Physiol Renal Physiol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. 2020, , 3412.
Cristina Maranto, Vindhya Udhane, Jing Jia, Ranjit Verma, Gerhard Müller-Newen, John D Imig

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death.
Marcus de Bourg, Abhishek Mishra, Rawand S Mohammad, Christophe Morisseau, Bruce D Hammock, John D Imig

Molecules· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypertension: A Continuing Public Healthcare Issue.
Samaneh Goorani, Somaye Zangene, John D Imig

Int J Mol Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats.
Olga Gawrys, Šárka Jíchová, Matúš Miklovič, Zuzana Husková, Soňa Kikerlová, John D Imig

Hypertens Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences.
Samaneh Goorani, Abdul Hye Khan, Abhishek Mishra, Ashraf El-Meanawy, John D Imig

Kidney Blood Press Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual soluble epoxide hydrolase inhibitor - farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis.
Md Abdul Hye Khan, Benjamin Nolan, Anna Stavniichuk, Daniel Merk, John D Imig

Front Immunol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Nuclear receptors in hemodynamics and blood pressure control.
John D Imig, Jing Wu, Eman Y Gohar

Front Physiol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peroxisome proliferator-activated receptors, farnesoid X receptor, and dual modulating drugs in hypertension.
John D Imig

Front Physiol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioactive lipids in hypertension.
John D Imig

Adv Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salt-sensitive hypertension after reversal of unilateral ureteral obstruction.
John D Imig, Md Abdul Hye Khan, Anna Stavniichuk, Wojciech K Jankiewicz, Samaneh Goorani

Biochem Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: The future of physiology: 2020 and beyond, Volume III.
John D Imig

Front Physiol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteopontin Regulates Phosphate Solubility to Prevent Mineral Aggregates in CKD.
John D Imig

Kidney360· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontiers in metabolic physiology grand challenges.
John D Imig

Front Physiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury.
John D Imig

Adv Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection.
John D Imig

Clin Sci (Lond)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Interactions Between Podocytes, Mesangial Cells, and Glomerular Endothelial Cells in Glomerular Diseases.
John D Imig, Xueying Zhao, Ahmed A Elmarakby, Tengis Pavlov

Front Physiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.
Kate C Chiang, John G Rizk, Deanna J Nelson, Lakshmanan Krishnamurti, Selvakumar Subbian, John D Imig

Expert Opin Ther Targets· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.
Iwona Baranowska, Olga Gawrys, Agnieszka Walkowska, Krzysztof H Olszynski, Luděk Červenka, John D Imig

Front Pharmacol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity.
Wojciech K Jankiewicz, Scott D Barnett, Anna Stavniichuk, Sung Hee Hwang, Bruce D Hammock, John D Imig

Front Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Target Drugs for Kidney Diseases.
John D Imig, Daniel Merk, Eugen Proschak

Kidney360· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis